JAK inhibition in the treatment of alopecia areata – a promising new dawn?

Ismail, Fathima Ferial; Sinclair, Rodney

doi:10.1080/17512433.2020.1702878

Cited by 33 publications

(21 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inhibition of the upstream pathway JAK appears as a plausible target for developing a therapy for hair loss [67]. In fact, a number of JAK inhibitors, such as tofacitinib, ruxolitinib, baricitinib, CTP-543, PF-06651600 and PF-06700841 are in the progress of developing a therapy for alopecia [71,72] more often in alopecia areata a common form of non-scarring hair loss that usually starts abruptly with a very high psychological impact [73], it is a T-cell-mediated disease which produces circular patches of non-scarring hair loss and nail dystrophy [72].…”

Section: Modulation Of Wnt/dickkopf Homolog 1 (Dkk1) Sonic Hedgehog (Shh) Jak-stat3 and Tgf-β Signaling By Ginsengmentioning

confidence: 99%

Ginseng in Hair Growth and Viability

Mercedes¹,

Ruymán²,

Noelia³

et al. 2022

Ginseng - Modern Aspects of the Famed Traditional Medicine

View full text Add to dashboard Cite

The hair follicle is the unique organ that has the capacity of undergoing cyclic transformations following periods of growth (anagen), regression (catagen), and rest (telogen) regenerating itself to restart the cycle. The dynamic capacity of hair to growth and rest enables mammals to control hair growth and length in different body side and to change their coats. Unlike what is observed in many animals in which the pelage synchronously passes from one phase of the cycle to other all stages of growth cycle are simultaneously found in the human pelage, the growth pattern is a mosaic where the hair cycling staging of one hair root is completely independent of it nearest hair follicle, meaning that each follicular unit (FU) can contain follicles in different stages at any given time. A variety of factors, such as nutritional status, hormones, exposure to radiations, chemotherapy or radiotherapy, environmental pollution or drugs may affect hair growth, and affects the number of hairs, this progressive hair loss has a cosmetic and social impact that often significantly affects social and psychological well-being of the patient that suffers from this hair loss. Although a number of therapies, such as finasteride and minoxidil, are approved medications, a wide variety of classes of phytochemicals and natural products, including those present in ginseng are being testing. The purpose of this chapter is to focus on study the potential of ginseng and its metabolites in hair loss.

show abstract

Section: Modulation Of Wnt/dickkopf Homolog 1 (Dkk1) Sonic Hedgehog (Shh) Jak-stat3 and Tgf-β Signaling By Ginsengmentioning

confidence: 99%

Ginseng in Hair Growth and Viability

Mercedes¹,

Ruymán²,

Noelia³

et al. 2022

Ginseng - Modern Aspects of the Famed Traditional Medicine

View full text Add to dashboard Cite

show abstract

“…Systematic reviews were envisioned as a way to provide busy clinicians with comprehensive, up‐to‐date syntheses of all available evidence. However, despite multiple reviews on the same topic, 2,3,7,8 recent reviews have failed to do this by overlooking unpublished trials. Although JAK inhibitors represent an exciting area of ongoing research, inclusion of the grey literature suggests less optimism for topical JAK inhibitors than is apparent in the published literature alone.…”

Section: Reportmentioning

confidence: 99%

The status and outcomes of registered clinical trials for Janus kinase inhibitors in alopecia areata: are unpublished trials being overlooked?

et al. 2021

View full text Add to dashboard Cite

Summary Recent meta‐analyses of Janus kinase (JAK) inhibitors in alopecia areata (AA) have excluded trial registries and may thus be subject to publication bias. This study assessed the potential for evidence selection bias and provides an overview of JAK inhibitor trials in AA. A broad search strategy of ClinicalTrials.gov was performed for AA. We also recorded whether results were published on PubMed. There were 26 trials identified, of which 9 were ongoing (mostly oral JAK inhibitors: 8 studies; 89%). Of completed/terminated trials, 4/17 (24%) had terminated prematurely, citing ‘inefficacy/futility’ or ‘sponsor decision’. These were all topical JAK inhibitor trials (4/8, 50% termination rate), with a 0% termination rate (0/9) for oral JAK inhibitor trials. We conclude that topical JAK inhibitors may be less efficacious than has been apparent in the literature to date, with 50% of trials having terminated due to inefficacy/futility or sponsor decision and only one topical JAK inhibitor trial ongoing.

show abstract

“…64 Although Janus kinase inhibitors recently have shown promising results in the treatment of AA, the need for prolonged therapy may be frustrating to patients. 66 Severity of AA also can vary, with 30% of patients experiencing extensive hair loss. 67 The use of CAM has been widely reported in AA due to high levels of dissatisfaction with existing therapies.…”

Section: Alopecia Areatamentioning

confidence: 99%